Galapagos - Model GLPG2737 - Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Inhibitor
From Other Programs
GLPG2737 is a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) inhibitor which was observed to be well tolerated by patients in previous clinical trials. It is hypothesized that inhibition of the CFTR channel might reduce cyst growth and enlargement for patients with autosomal dominant polycystic kidney disease (ADPKD). In December 2020, we announced the first dosing with GLPG2737 in the Phase 2 MANGROVE trial in patients with ADPKD and in November 2021 full patient recruitment with topline results anticipated in the first half of 2023.
-
Most popular related searches
Customer reviews
No reviews were found for Galapagos - Model GLPG2737 - Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Inhibitor. Be the first to review!